Dynavax to Present at Credit Suisse 2007 Healthcare Conference
Posted on: Friday, 9 November 2007, 09:00 CST
BERKELEY, Calif., Nov. 9 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation announced today Dino Dina, President and CEO, will present an overview of the company at the Credit Suisse 2007 Healthcare Conference in Phoenix, Arizona on Tuesday, November 13th at 4:00 p.m. MST (6:00 p.m. EST). The presentation will be webcast.
To access the live audio broadcast and the subsequent archived audio recording of the company presentation, please log onto the company's website at http://www.dynavax.com/ under the "Investors'" section.
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAV(TM), a hepatitis B vaccine in Phase 3 partnered with Merck & Co. Inc.; TOLAMBA(TM), a ragweed allergy immunotherapy in Phase 2; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. The National Institutes of Health (NIH) partially funds our preclinical work on a vaccine for influenza. Symphony Dynamo, Inc. (SDI) funds our colorectal cancer trials and our preclinical hepatitis C therapeutic program, and Deerfield Management has committed funding for our allergy programs. While Deerfield, NIH and SDI provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization. For more information, please visit http://www.dynavax.com/.
Dynavax Technologies Corporation
CONTACT: investors, Shari Annes of Dynavax Technologies Corporation,+1-650-888-0902, sannes@dynavax.com
Web site: http://www.dynavax.com/
Source: PRNewswire-FirstCall
Related Articles
- Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
- Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
- High Desert Gold Corporation Completes Phase 1 Diamond Drilling Program at the Canasta Dorada Property in Sonora, Mexico
- ArQule Enrolls First Patient in Phase 1/2 Clinical Trial Program of ARQ 197 in Non-Small Cell Lung Cancer
- Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
- Human Genome Sciences Announces Phase 3 Clinical Development Program for Albuferon(TM) in Chronic Hepatitis C
- Applied Genetic Technologies Corporation Announces Initiation of Phase 1 Clinical Study on Safety of AGTC-0106
- Dynavax Initiates US-Based Phase 1 Clinical Trial of HEPLISAV(TM) Hepatitis B Vaccine in Dialysis Population
- Gilead Sciences Announces Initiation of Phase III Clinical Program Evaluating Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B Virus
- A.P. Pharma Initiates APF530 Phase 2 Clinical Trial Program in Cancer Patients
 |
 |
User Comments (0)
RSS Feeds